← Back to Search
A Review Of Coumarin Derivatives In Pharmacotherapy Of Breast Cancer.
M. Musa, J. Cooperwood, M. O. Khan
Published 2008 · Chemistry, Medicine
Save to my Library
Download via 🐼 PaperPanda Download via oaDOI Download via OAB Download via LibKey Download via Google Google ScholarAnalyze on Scholarcy Visualize in Litmaps
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
The coumarin (benzopyran-2-one, or chromen-2-one) ring system, present in natural products (such as the anticoagulant warfarin) that display interesting pharmacological properties, has intrigued chemists and medicinal chemists for decades to explore the natural coumarins or synthetic analogs for their applicability as drugs. Many molecules based on the coumarin ring system have been synthesized utilizing innovative synthetic techniques. The diversity oriented synthetic routes have led to interesting derivatives including the furanocoumarins, pyranocoumarins, and coumarin sulfamates (COUMATES), which have been found to be useful in photochemotherapy, antitumor and anti-HIV therapy, and as stimulants for central nervous system, antibacterials, anti-inflammatory, anti-coagulants, and dyes. Of particular interest in breast cancer chemotherapy, some coumarins and their active metabolite 7-hydroxycoumarin analogs have shown sulfatase and aromatase inhibitory activities. Coumarin based selective estrogen receptor modulators (SERMs) and coumarin-estrogen conjugates have also been described as potential antibreast cancer agents. Since breast cancer is the second leading cause of death in American women behind lung cancer, there is a strong impetus to identify potential new drug treatments for breast cancer. Therefore, the objective of this review is to focus on important coumarin analogs with antibreast cancer activities, highlight their mechanisms of action and structure-activity relationships on selected receptors in breast tissues, and the different methods that have been applied in the construction of these pharmacologically important coumarin analogs.
This paper references
Coumestrol, a new estrogen isolated from forage crops.
E. Bickoff (1957)
Esters of methanesulfonic acid as irreversible inhibitors of acetylcholinesterase.
R. Kitz (1962)
CENTRAL NERVOUS SYSTEM DEPRESSANTS. VII. PYRIDYL COUMARINS.
R. Moffett (1964)
The oestrogenic and anti-oestrogenic activity of some synthetic steroids and non-steroids.
I. Pollard (1968)
Mirestrol. I. Preparation of the tricyclic intermediate.
M. Miyano (1972)
Inhibition and enhancement of mammary tumorigenesis by 7,12-dimethylbenz (a) anthracene in the female sprague-dawley rat.
G. Feuer (1974)
Progress in the chemistry of organic natural products
J. Harborne (1975)
Suppression of 7,12-Dimethylbenz(α) Anthracene-Induced Breast Carcinoma by Coumarin in the Rat
G. Feuer (1976)
Melanotropin–daunomycin conjugate shows receptor-mediated cytotoxicity in cultured murine melanoma cells
J. Varga (1977)
Inhibition of Chemical Carcinogen-induced Neoplasia by Coumarins and α-Angelicalactone
L. Wattenberg (1979)
Cancer of the breast: the past decade (first of two parts).
I. Henderson (1980)
The natural coumarins : occurrence, chemistry, and biochemistry
R. D. Murray (1982)
In situ estrogen production via the estrone sulfatase pathway in breast tumors: relative importance versus the aromatase pathway.
S. Santner (1984)
Importance of estrogen sulfates in breast cancer.
J. Pasqualini (1989)
Realizing the full potential of immunotoxins.
W. Blättler (1989)
Diethylstilbestrol-linked cytotoxic agents: synthesis and binding affinity for estrogen receptors.
K. Krohn (1989)
The Rarity of Liver Toxicity in Patients Treated with Coumarin (1, 2-Benzopyrone)
D. Cox (1989)
The pharmacology, metabolism, analysis, and applications of coumarin and coumarin-related compounds.
D. Egan (1990)
Highly selective inhibition of estrogen biosynthesis by CGS 20267, a new non-steroidal aromatase inhibitor
A. Bhatnagar (1990)
Metabolism of the 4-iodo derivative of tamoxifen by isolated rat hepatocytes. Demonstration that the iodine atom reduces metabolic conversion and identification of four metabolites.
R. Mccague (1990)
Phase I evaluation of coumarin (1,2-benzopyrone) and cimetidine in patients with advanced malignancies.
M. Marshall (1991)
Interactions of a series of coumarins with reactive oxygen species. Scavenging of superoxide, hypochlorous acid and hydroxyl radicals.
M. Payá (1992)
Multistage carcinogenesis in mouse skin.
J. DiGiovanni (1992)
Phase II evaluation of coumarin (1,2‐benzopyrone) in metastatic prostatic carcinoma
J. Mohler (1992)
Treatment of lymphedema of the arms and legs with 5,6-benzo-[alpha]-pyrone.
J. Casley-Smith (1993)
Peptide-linked 1,3-dialkyl-3-acyltriazenes: gastrin receptor directed antineoplastic alkylating agents.
B. Schmidt (1994)
Estrogen receptors (ER) in human breast cancer. The significance of a new prognostic factor based on both ER protein and ER mRNA contents
M. Gotteland (1994)
Inactivation of steroid sulfatase by an active site-directed inhibitor, estrone-3-O-sulfamate.
A. Purohit (1995)
Frequency of coumarin hepatotoxicity
John R. Casley‐Smith (1995)
A novel amino acid modification in sulfatases that is defective in multiple sulfatase deficiency
B. Schmidt (1995)
Comprehensive heterocyclic chemistry II
A. Katritzky (1996)
Overexpression of int-5/aromatase in mammary glands of transgenic mice results in the induction of hyperplasia and nuclear abnormalities.
R. Tekmal (1996)
New aromatase inhibitors: more selectivity, less toxicity, unfortunately, the same activity.
M. Castiglione-Gertsch (1996)
Pharmacological and biochemical actions of simple coumarins: natural products with therapeutic potential.
J. Hoult (1996)
Variation of hormonal receptor, pS2, c-erbB-2 and GSTpi contents in breast carcinomas under tamoxifen: a study of 74 cases.
I. Soubeyran (1996)
A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer.
W. Jonat (1996)
In vivo activity of 4-methylcoumarin-7-O-sulfamate, a nonsteroidal, nonestrogenic steroid sulfatase inhibitor.
A. Purohit (1996)
Design, Synthesis, and Biological Evaluation of Ellipticine‐Estradiol Conjugates.
R. Devraj (1996)
Active site directed inhibition of estrone sulfatase by nonsteroidal coumarin sulfamates.
L. Woo (1996)
Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer.
J. Geisler (1996)
Synthesis and sulfatase inhibitory activities of non-steroidal estrone sulfatase inhibitors
P. Li (1996)
Comparison of the Ligand Binding Specificity and Transcript Tissue Distribution of Estrogen Receptors α and β.
G. Kuiper (1997)
Aromatase activity and expression in breast cancer and benign breast tissue stromal cells.
S. J. Santner (1997)
Structure of a human lysosomal sulfatase.
C. S. Bond (1997)
Structure -Cytotoxicity Relationships of a Series of Natural and Semi-Synthetic Simple Coumarins as Assessed in Two Human Tumour Cell Lines
H. Kolodziej (1997)
Effect of naturally occurring coumarins on the formation of epidermal DNA adducts and skin tumors induced by benzo[a]pyrene and 7,12-dimethylbenz[a]anthracene in SENCAR mice.
Y. Cai (1997)
Comprehensive heterocyclic chemistry on CD-ROM
A. Katritzky (1997)
The development of A-ring modified analogues of oestrone-3-O-sulphamate as potent steroid sulphatase inhibitors with reduced oestrogenicity
A. Purohit (1998)
Sulfatases, Trapping of the Sulfated Enzyme Intermediate by Substituting the Active Site Formylglycine *
M. Recksiek (1998)
Antitumor-activities of coumarin, 7-hydroxy-coumarin and its glucuronide in several human tumor cell lines.
U. Weber (1998)
Crystal structure of human arylsulfatase A: the aldehyde function and the metal ion at the active site suggest a novel mechanism for sulfate ester hydrolysis.
G. Lukatela (1998)
Selective estrogen receptor modulators (SERMs).
T. Grese (1998)
Novel antineoplastic agents with efficacy against multidrug resistant tumor cells.
J. Medina (1998)
Residues critical for formylglycine formation and/or catalytic activity of arylsulfatase A.
A. Knaust (1998)
In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients.
J. Geisler (1998)
Preclinical studies using the intratumoral aromatase model for postmenopausal breast cancer.
A. Brodie (1998)
Steroidal and nonsteroidal sulfamates as potent inhibitors of steroid sulfatase.
L. Woo (1998)
Definition of the molecular mechanism of action of tissue-selective oestrogen-receptor modulators.
D. McDonnell (1998)
Comparative molecular field analysis of non-steroidal aromatase inhibitors: an extended model for two different structural classes.
M. Recanatini (1998)
Selective, covalent modification of beta-tubulin residue Cys-239 by T138067, an antitumor agent with in vivo efficacy against multidrug-resistant tumors.
B. Shan (1999)
Postmenopausal hormone therapy, SERMs, and coronary heart disease in women
Nanette K. Wenger (1999)
Comparative Analyses of Mechanistic Differences Among Antiestrogens1.
A. Wijayaratne (1999)
[Binding affinity to steroid hormone receptors and antiproliferative action on MCF-7 cells of coumarin derivatives and isoflavonoids].
S. Kirkiacharian (1999)
Steroid sulfatase expression is an independent predictor of recurrence in human breast cancer.
T. Utsumi (1999)
The Molecular Pharmacology of SERMs
D. McDonnell (1999)
Aromatase inhibitors and their antitumor effects in model systems.
A. Brodie (1999)
Aromatase overexpression and breast hyperplasia, an in vivo model--continued overexpression of aromatase is sufficient to maintain hyperplasia without circulating estrogens, and aromatase inhibitors abrogate these preneoplastic changes in mammary glands.
R. Tekmal (1999)
Estrogen, DNA damage and mutations.
D. Roy (1999)
Synthesis and estrogen receptor binding affinity of a porphyrin-estradiol conjugate for targeted photodynamic therapy of cancer.
D. James (1999)
The potential of aromatase inhibitors in breast cancer prevention.
R. Santen (1999)
Actions of dehydroepiandrosterone and its sulfate in the central nervous system: effects on cognition and emotion in animals and humans
O. Wolf (1999)
Trends Endocrinol. Metab
DP McDonnell (1999)
Raloxifene: A selective estrogen receptor modulator (SERM) with multiple target system effects.
D. Muchmore (2000)
In vivo inhibition of estrone sulfatase activity and growth of nitrosomethylurea-induced mammary tumors by 667 COUMATE.
A. Purohit (2000)
Improved antibacterial activities of coumarin antibiotics bearing 5',5'-dialkylnoviose: biological activity of RU79115.
B. Musicki (2000)
Inhibition of steroid sulphatase activity by tricyclic coumarin sulphamates
B. Malini (2000)
New fluorogenic substrate for the first continuous steroid sulfatase assay.
M. Bilban (2000)
Potent active site-directed inhibition of steroid sulphatase by tricyclic coumarin-based sulphamates.
L. Woo (2000)
Selective estrogen receptor modulators: structure, function, and clinical use.
C. Osborne (2000)
Non-steroidal and steroidal sulfamates: new drugs for cancer therapy
A. Purohit (2001)
In vitro and in vivo biologic effects of Ospemifene (FC-1271a) in breast cancer
T. L. Taras (2001)
Genotoxicity of the steroidal oestrogens oestrone and oestradiol: possible mechanism of uterine and mammary cancer development.
J. Liehr (2001)
Evaluation of the mechanism of aromatase cytochrome P450. A site-directed mutagenesis study.
Y. C. Kao (2001)
Substituted Benzopyranobenzothiazinones. Synthesis and Estrogenic Activity on MCF‐7 Breast Carcinoma Cells.
Y. Jacquot (2001)
Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study.
W. Eiermann (2001)
Flexible estrogen receptor modulators: design, synthesis, and antagonistic effects in human MCF-7 breast cancer cells.
M. J. Meegan (2001)
Crystal structure of an enzyme-substrate complex provides insight into the interaction between human arylsulfatase A and its substrates during catalysis.
R. von Bülow (2001)
Effects of SP500263, a novel, potent antiestrogen, on breast cancer cells and in xenograft models.
H. Brady (2002)
Review of estrone sulfatase and its inhibitors--an important new target against hormone dependent breast cancer.
Sabbir Ahmed (2002)
Sulfonation and molecular action.
C. Strott (2002)
The naturally occurring coumarins.
R. D. Murray (2002)
Synthesis and biochemical evaluation of novel and potent inhibitors of the enzyme oestrone sulphatase (ES)
Sabbir Ahmed (2002)
SERMs: how do they work?
M. Draper (2002)
Natural and synthetic geiparvarins are strong and selective MAO-B inhibitors. Synthesis and SAR studies.
A. Carotti (2002)
Differential Response of Estrogen Receptors α and β to SP500263, a Novel Potent Selective Estrogen Receptor Modulator
H. Brady (2002)
An estradiol-porphyrin conjugate selectively localizes into estrogen receptor-positive breast cancer cells.
N. Swamy (2002)
MW Draper (2002)
SP500263, a novel SERM, blocks osteoclastogenesis in a human bone cell model: role of IL-6 and GM-CSF.
M. K. Kung Sutherland (2003)
Intratumoural mRNA expression of genes from the oestradiol metabolic pathway and clinical and histopathological parameters of breast cancer
N. Yoshimura (2003)
In vitro and in vivo models for the evaluation of new inhibitors of human steroid sulfatase, devoid of residual estrogenic activity
J. Shields-Botella (2003)
High expression of steroid sulfatase mRNA predicts poor prognosis in patients with estrogen receptor-positive breast cancer.
Y. Miyoshi (2003)
Aromatase inhibitors as adjuvant therapies in patients with breast cancer
R. Coombes (2003)
Anticancer and antiviral sulfonamides.
A. Scozzafava (2003)
Inhibition of MCF-7 breast cancer cell proliferation and in vivo steroid sulphatase activity by 2-methoxyoestradiol-bis-sulphamate
B. Raobaikady (2003)
[Synthesis and binding affinity of 3-aryl-7-hydroxycoumarins to human alpha and beta estrogen receptors].
S. Kirkiacharian (2003)
Estrogen sulfotransferase and steroid sulfatase in human breast carcinoma.
T. Suzuki (2003)
17β-Estradiol responsiveness of MCF-7 laboratory strains is dependent on an autocrine signal activating the IGF type I receptor
I. H. Hamelers (2003)
Steroid sulphatase inhibitors for breast cancer therapy
A. Purohit (2003)
Docking studies of sulphamate inhibitors of estrone sulphatase in human carbonic anhydrase II.
N. Vicker (2003)
Cytotoxic effects, alkylating properties and molecular modelling of coumarin derivatives and their phosphonic analogues.
E. Budzisz (2003)
Novel coumarin derivatives of heterocyclic compounds as lipid-lowering agents.
G. R. Madhavan (2003)
The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer.
S. Howell (2004)
Genotoxicity of steroidal estrogens
J. Russo (2004)
Selective estrogen receptor modulation: concept and consequences in cancer.
V. Jordan (2004)
Steroid sulfatase inhibitors
P. Nussbaumer (2004)
Synthesis and binding affinity to human α and β estrogen receptors of various 7-hydroxycoumarins substituted at 4- and 3,4- positions
S. Kirkiacharian (2004)
Design, synthesis, and bioactivities of steroid-linked taxol analogues as potential targeted drugs for prostate and breast cancer.
Changhui Liu (2004)
Effects of Fadrozole (CGS 16949A) and Letrozole (CGS 20267) on the inhibition of aromatase activity in breast cancer patients
L. Demers (2004)
Arimidex®: A potent and selective fourth-generation aromatase inhibitor
P. Plourde (2004)
Lead identification of a potent benzopyranone selective estrogen receptor modulator.
J. A. Mckie (2004)
Synthesis and Relative Binding Affinity to Human Steroid Receptors of Substituted 3‐Aryloxycoumarins.
R. Bakhchinian (2004)
Design, synthesis, and 3D QSAR of novel potent and selective aromatase inhibitors.
F. Leonetti (2004)
Studies on coumarins and coumarin-related compounds to determine their therapeutic role in the treatment of cancer.
A. Lacy (2004)
Natural and synthetic coumarin derivatives with anti-inflammatory/ antioxidant activities.
K. Fylaktakidou (2004)
Biochemical and Biological Characterization of a Novel Anti-aromatase Coumarin Derivative*
S. Chen (2004)
Are all aromatase inhibitors the same? A review of the current evidence.
F. Jänicke (2004)
Synthesis of new coumarin 3-(N-aryl) sulfonamides and their anticancer activity.
N. Reddy (2004)
Novel coumarin-3-(N-aryl)carboxamides arrest breast cancer cell growth by inhibiting ErbB-2 and ERK1.
N. Reddy (2005)
Photophysical and (photo)electrochemical properties of a coumarin dye.
Z. Wang (2005)
Chemical aspects of coumarin compounds for the prevention of hepatocellular carcinomas.
T. Okamoto (2005)
Benefit with aromatase inhibitors in the adjuvant setting for postmenopausal women with breast cancer.
H. Mouridsen (2005)
Crystal structure of human carbonic anhydrase II at 1.95 A resolution in complex with 667-coumate, a novel anti-cancer agent.
M. Lloyd (2005)
Simple coumarins and analogues in medicinal chemistry: occurrence, synthesis and biological activity.
F. Borges (2005)
An updated review of the clinical development of coumarin (1,2-benzopyrone) and 7-hydroxycoumarin
M. Marshall (2005)
Treatment with coumarin to prevent or delay recurrence of malignant melanoma
R. Thornes (2005)
Steroid sulfatase: molecular biology, regulation, and inhibition.
M. Reed (2005)
Pharmaceutical prospects of phytoestrogens.
T. Usui (2006)
Structure-Activity Relationships of Synthetic Coumarins as HIV-1 Inhibitors
I. Kostova (2006)
Phase I Study of STX 64 (667 Coumate) in Breast Cancer Patients: The First Study of a Steroid Sulfatase Inhibitor
S. Stanway (2006)
What do we know about the mechanisms of aromatase inhibitor resistance?
Shiuan Chen (2006)
Synthesis and biological activities of nucleoside-estradiol conjugates.
H. Ali (2006)
Aromatase inhibition and very low dose estradiol add-back: A pilot study for novel breast cancer prevention.
A. Kendall (2006)
Synthesis, Characterization, and Cytotoxic Activity of New Lanthanum(III) Complexes of Bis-Coumarins
I. Kostova (2006)
Summary of aromatase inhibitor trials: The past and future
P. Goss (2007)
Synthesis, characterization, and estrogen receptor binding affinity of flavone-, indole-, and furan-estradiol conjugates.
Naseem Ahmed (2007)
Antitumor agents. 258. Syntheses and evaluation of dietary antioxidant--taxoid conjugates as novel cytotoxic agents.
Kyoko Nakagawa-Goto (2007)
Synthesis, computational study and cytotoxic activity of new 4-hydroxycoumarin derivatives.
S. Stanchev (2008)
This paper is referenced by
Synthesis, Characterization, and Cytotoxic Evaluation of New Triazole Derivatives of Osthol
Z. Rather (2021)
Design and synthesis of new series of dipyrromethane-coumarin and porphyrin-coumarin derivatives: Excellent anticancer agents
Megharaja Holiyachi (2021)
Synthesis and evaluation of the antagonistic activity of 3-acetyl-2H-benzo[g]chromen-2-one against mutant Y537S estrogen receptor alpha via E-Pharmacophore modeling, molecular docking, molecular dynamics, and in-vitro cytotoxicity studies
R. Shylaja (2021)
Phytochemical Investigation of New Algerian Lichen Species: Physcia Mediterranea Nimis
M. Kerboua (2021)
In vitro and in silico molecular docking studies of Rheum emodi-derived diamagnetic SnO2 nanoparticles and their cytotoxic effects against breast cancer
D. Sharma (2021)
An efficient approach for the synthesis and antimicrobial evaluation of some new benzocoumarins and related compounds
Mohamed H. Hekal (2021)
Quantum chemical computations, fluorescence spectral features and molecular docking of two biologically active heterocyclic class of compounds
R. Melavanki (2021)
Deverra tortuosa (Desf.) DC from Saudi Arabia as a new source of marmin and furanocoumarins derivatives with α-glucosidase, antibacterial and cytotoxic activities
M. Oueslati (2021)
Base‐Promoted Direct Cascade Transformation of Chromones to Coumarins via Benzannulation and Transesterification
Hongyun Cai (2021)
Delivery of novel coumarin-dihydropyrimidinone conjugates through mixed polymeric nanoparticles to potentiate therapeutic efficacy against triple-negative breast cancer.
Avijit Ghosh (2021)
A synergetic role of Aegle marmelos fruit ash in the synthesis of biscoumarins and 2-amino-4H-chromenes
R. C. Patil (2021)
Aryl hydrazones linked thiazolyl coumarin hybrids as potential urease inhibitors
Uzma Salar (2021)
Synthesis of Ni(II), Cu(II) and Zn(II) coumarin-3-carboxilic acid derivates and their and their physical-chemical properties
Dirceu Aparecido Gonçalves de Souza (2021)
Synthesis, structural characterization, biological activity and molecular docking study of 4,7-dihydroxycoumarin modified by aminophenol derivatives
Ziko Milanovic (2021)
Engagement of phytoestrogens in breast cancer suppression: Structural classification and mechanistic approach.
A. Tanwar (2020)
Interaction of amphiphilic coumarin with DPPC/DPPS lipid bilayer: effects of concentration and alkyl tail length.
Poornima Kalyanram (2020)
Formation of epoxychromeno[4,3-c]isoquinolines through diastereoselective one-pot IMDA reaction of 4-chloro-3-[(1E)-3-oxo-3-phenyl-1-propen-1-yl]-2H-chromen-2-one and furfurylamine
A. Alizadeh (2020)
Synthesis, characterization, structural exploration and quantum chemical calculations of (E)-8-(1-((4-aminobenzyl)imino)ethyl)-7-hydroxy-4-methyl-coumarin
Chethan Prathap K. N (2020)
Recent progress in selective estrogen receptor downregulators (SERDs) for the treatment of breast cancer.
Synthesis, spectroscopic characterization, biological activity, DFT and molecular docking study of novel 4-hydroxycoumarine derivatives and corresponding palladium(II) complexes
Edina H Avdović (2020)
Functional Dyes in Polymeric 3D Printing: Applications and Perspectives
M. Gastaldi (2020)
Promising Lead Compounds in the Development of Potential Clinical Drug Candidate for Drug-Resistant Tuberculosis
Saad Alghamdi (2020)
Pharmacological Activities of Coumarin Compounds in Licorice: A Review
Yimei Zang (2020)
In silico molecular docking studies and MM/GBSA analysis of coumarin-carbonodithioate hybrid derivatives divulge the anticancer potential against breast cancer
Shridhar V Pattar (2020)
Coumarins and Coumarin-Related Compounds in Pharmacotherapy of Cancer
Esra Küpeli Akkol (2020)
Chemical profiling of a polyherbal formulation by tandem mass spectroscopic analysis with multiple ionization techniques
Sulaiman C. T. (2020)
Quantum chemical computations and photophysical spectral features studies of two coumarin compounds.
Kalpana K. Sharma (2020)
Recent progress on coumarinscaffold‐basedanti‐microbial agents (PartIII)
M. Gouda (2020)
Rational synthetic methods in creating promising (hetero)aromatic molecules and materials
G. Zyryanov (2020)
Coumarins modulate the anti-glioma properties of temozolomide.
Joanna Sumorek-Wiadro (2020)
Melanogenesis Effect of 7-acetoxy-4-methylcoumarin in B16F10 Melanoma Cells
J. Sim (2020)
Microwave- and ultrasound-assisted heterocyclics synthesis in aqueous media
H. Abdullah (2020)See more